Preferred Label : Mucopolysaccharidosis, type iiia;
Symbol : MPS3A;
CISMeF acronym : MPS3A;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Sanfilippo syndrome a; Heparan sulfate sulfatase deficiency; Sulfamidase deficiency; Mps iiia;
Description : The Sanfilippo syndrome, or mucopolysaccharidosis III, is an autosomal recessive lysosomal
storage disease due to impaired degradation of heparan sulfate (Esposito et al., 2000).
The disorder is characterized by severe central nervous system degeneration, but only
mild somatic disease. Onset of clinical features usually occurs between 2 and 6 years;
severe neurologic degeneration occurs in most patients between 6 and 10 years of age,
and death occurs typically during the second or third decade of life. Type A has been
reported (van de Kamp et al., 1981) to be the most severe, with earlier onset and
rapid progression of symptoms and shorter survival. - Genetic Heterogeneity of Mucopolysaccharidosis
Type III MPS III includes 4 types, each due to the deficiency of a different enzyme:
heparan N-sulfatase (type A); alpha-N-acetylglucosaminidase (type B; 252920); acetyl
CoA:alpha-glucosaminide acetyltransferase (type C; 252930); and N-acetylglucosamine
6-sulfatase (type D; 252940).;
Inheritance : Autosomal recessive;
Molecular basis : Caused by mutations in the heparan sulfate sulfatase gene (SGSH, 605270.0001);
Laboratory abnormalities : Heparan N-sulfatase deficiency in fibroblasts and amniocytes; Heparan sulfate excretion in urine;
Prefixed ID : #252900;
Origin ID : 252900;
UMLS CUI : C0086647;
Automatic exact mappings (from CISMeF team)
Broader ORDO disease(s)
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT